In this role, you will
- Discover and develop new small molecule therapeutics for severe disorders in a collaborative research setting.
- Develop cell lines and disease relevant models for interrogation of mechanism of action studies to support early and late-stage programs.
- Perform studies to study target engagement between SAR compounds and target proteins in live cells.
- Maintain cell lines and models for routine characterization of novel SAR compounds for both 2D and spheroids.
- Document findings and record data in electronic notebook.
What you'll bring
- Experience in Cancer Biology and driving a research program with data analysis generating hypotheses.
- Sr. Research Associate: Bachelor of Science with 2-3+ years of industry experience or Master of Science with some industry experience OR
- Scientist: Bachelor of Science with 6+ years of industry experience or Master of Science with 3-4+ years of industry experience
- Experience in mammalian cell culture in generating and maintaining reporter cell lines.
- Experience with the Promega HiBiT and NanoBRET target engagement platform.
- Understanding in Chemical Biology techniques: photoaffinity labeling, chemical target identification, and LC-MS/MS or LC-MS.
- Understanding of western blot, ELISA, qRT-PCR, and immunofluorescence techniques.
- Familiarity with phenotypic assays: cell growth, apoptosis, and cell cycle.
- Scientific and technology knowledge of RNAi and CRISPR techniques.
- Understanding of designing DNA vector constructs for reporters and overexpression mammalian model systems.
- High attention to detail and strong math skillsStrong oral and written communication skills.
- Experience with Graphpad prism, Snapgene, Excel, and Powerpoint.
Similar Jobs
What We Do
Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery. We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines. Genesis raised its $52M Series A from top tech + biotech investors, Andreessen Horowitz, Rock Springs, and T. Rowe Price. Story: https://techcrunch.com/2020/12/02/genesis-therapeutics-raises-52m-a-round-for-its-ai-focused-drug-discovery-mission/ We deploy our technology to accelerate a pipeline of several internal drug programs. Furthermore, Genesis has announced two significant, multi-target collaborations with Genentech and with Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. Now we are scaling the team and technology to support many more programs in parallel as well as increasingly difficult protein targets. We currently have a team (genesistherapeutics.ai/company.html#team) of about 35 people, split 50/50 between our ML / software team and our biochem team of veteran drug hunters in our own wetlab space. Our ML + software engineers are top-notch -- many graduates from MIT, UC Berkeley, Stanford. Previously worked at OpenAI, Google, Facebook, MemSQL, Jane Street, Dropbox, etc. We're recruiting pure ML research scientists + software engineers (no bio or chem experience expected) to further our core AI platform as well as scale our drug pipeline. Likewise, we have several openings in chemistry and biology to join our team of biotech + pharma veterans who are deploying the Genesis ML platform to discover novel drug candidates. Please apply on our website, or feel free to reach out via email directly: [email protected]
